Topiramate monotherapy in the maintenance treatment of bipolar I disorder: effects on mood, weight and serum lipids.
Topiramate is a newly developed anticonvulsant agent with possible mood-stabilizing properties. Little is known about the short- and long-term effects of topiramate monotherapy in bipolar disorder. We here present the case of a 60-year-old female bipolar patient who received topiramate alone as maintenance treatment after recovering from euphoric mania. During 7 months, she was free from new manic symptomatology and she was able to reduce her overweight by 16.5 kg. The patient who is known to have a strongly hyperthymic temperament described symptoms of fatigue and sedation and eventually discontinued topiramate monotherapy. When she presented again in our bipolar clinic, severe euphoric mania had developed. After hospitalization, she slowly responded to oral sodium valproate loading plus zotepine. Her weight increased again and so did her triglyceride serum levels. Topiramate treatment and discontinuation did not seem to affect cholesterol serum levels.
Erfurth
A
A
Department of Psychiatry, University of Münster, Germany. erfurth@uni-muenster.de
Kuhn
G
G
D000328:Adult; D000339:Affect / Q000187:drug effects*; D001714:Bipolar Disorder / Q000145:classification / Q000188:drug therapy* / Q000523:psychology; D001835:Body Weight / Q000187:drug effects*; D005260:Female; D005632:Fructose / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008055:Lipids / Q000097:blood*; D018696:Neuroprotective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000077236:Topiramate
D008055:Lipids; D018696:Neuroprotective Agents; D000077236:Topiramate; D005632:Fructose